Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine + esketamine is an intravenous combination therapy being investigated for the management of postoperative pain and recovery, specifically in patients undergoing liver cancer surgery. Lidocaine is a local anesthetic and anti-arrhythmic that acts as a sodium channel blocker, while esketamine (the S-enantiomer of ketamine) is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with analgesic and anesthetic properties. The combination aims to leverage multimodal analgesia to reduce opioid consumption and improve postoperative outcomes. This specific study is sponsored by West China Hospital, Sichuan University.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + esketamine.